首页> 外文期刊>Clinical, Cosmetic and Investigational Dermatology >Effects of topical 0.8% piroxicam and 50+ sunscreen filters on actinic keratosis in hypertensive patients treated with or without photosensitizing diuretic drugs: an observational cohort study
【24h】

Effects of topical 0.8% piroxicam and 50+ sunscreen filters on actinic keratosis in hypertensive patients treated with or without photosensitizing diuretic drugs: an observational cohort study

机译:一项观察性队列研究:局部用0.8%吡罗昔康和50+防晒过滤剂对接受或不接受光敏利尿药的高血压患者的光化性角化病的影响

获取原文
           

摘要

Background: Photosensitizing diuretics use (especially thiazide compounds) is associated with a significantly higher risk of squamous cell carcinoma (SCC). Actinic keratosis (AK) is a precursor of SCC. Study aim: To evaluate in a prospective cohort study the efficacy of topical piroxicam 0.8% and sunscreen 50+ (ACTX) in the treatment of AK in hypertensive subjects with or without TD treatment. Subjects and methods: A total of 119 hypertensive subjects with multiple AK (39 under chronic TD treatment; and 80 treated with other non-TD, non-photosensitizing antihypertensive drugs) were enrolled after their informed consent in a 6-month observational cohort study. All the subjects were treated with ACTX twice daily. The primary endpoint was the evolution of AK lesions at baseline, after 3 and 6 months. The secondary endpoint was the clearance of AK target lesions and field of cancerization by dermoscopic evaluation using a score evaluating erythema, scaling, pigmentation, and follicular plugs (ESPFP score; ranging from 0 to 20). An investigator, unaware of the type of antihypertensive treatments (TD or non-TD), performed all the clinical and dermoscopy evaluations. Results: At baseline, AK mean (SD) lesion number in TD group was 14.1(4) and 14.6(4) in the non-TD group. ESPFP mean (SD) score at baseline was 5.8(1.2) in both groups. A significant reduction of AK lesions in comparison with baseline was observed in both groups. A statistically significant greater reduction was observed in TD in comparison with the non-TD group (?54% vs ?32%). ESPFP score was reduced in a higher proportion in the TD group in comparison with the non-TD group (?60% vs ?37%, respectively). ACTX treatment was very well tolerated. Conclusion: In hypertensive subjects with multiple AK, the topical use of ACTX is associated with a significant reduction of lesions count with an improvement in the field cancerization. The clinical efficacy is more pronounced in subjects under thiazide diuretics treatment.
机译:背景:使用光敏利尿剂(尤其是噻嗪类化合物)与鳞状细胞癌(SCC)的风险明显较高有关。光化性角化病(AK)是SCC的前体。研究目的:在一项前瞻性队列研究中,评估局部使用吡罗昔康0.8%和防晒霜50+(ACTX)在有或没有TD治疗的高血压受试者中治疗AK的疗效。受试者和方法:经过6个月的观察性队列研究,在知情同意后,共有119名患有多发性AK的高血压受试者(39名在长期TD治疗下; 80例接受其他非TD,非光敏抗高血压药物治疗)。所有受试者每天两次接受ACTX治疗。主要终点是3个月和6个月后基线时AK病变的演变。次要终点是通过评估红斑,脱屑,色素沉着和滤泡堵塞的评分(ESPFP评分;范围从0到20),通过皮肤镜检查评估AK目标病变的清除率和癌变范围。一名研究人员不了解降压治疗的类型(TD或非TD),进行了所有临床和皮肤镜检查评估。结果:基线时,TD组的AK平均(SD)病变数为14.1(4),而非TD组为14.6(4)。两组在基线时的ESPFP平均值(SD)得分均为5.8(1.2)。两组均观察到AK损伤较基线明显减少。与非TD组相比,TD的减少量具有统计学意义(54%vs.32%)。与非TD组相比,TD组的ESPFP得分降低的比例更高(分别为60%和37%)。 ACTX治疗耐受性非常好。结论:在患有多个AK的高血压受试者中,ACTX的局部使用与病灶数的显着减少以及野外癌变的改善相关。在接受噻嗪类利尿剂治疗的受试者中,临床疗效更为明显。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号